The company, which largely remains in stealth mode, has set itself a mission of increasing the human lifespan by a decade.

Retro Biosciences, a US-based company focused on the cellular drivers of aging, has emerged with $180m in funding from undisclosed investors. The company was co-founded by Sheng Ding, who holds appointments at Gladstone Institutes, University of California (UC), San Francisco, Tsinghua University and Global Health Drug Discovery Institute. Retro remains in stealth mode – it…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.

Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).